Table 1.
Clinical and demographic information of the patients and healthy controls.
| mRS | Steroids | AEDs | Antidepressants or anti-anxiety meds | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paticipant | Sex | Age | Education | NMDAR-IgG CSF at onset | Acute disease symptoms | Paraneoplastic syndrome | Before treatment | T1 | T2 | T3 | Treatment | T1 | T2 | T3 | T1 | T2 | T3 | T1 | T2 | T3 |
| Patient_1 | F | 22 | 12 | 1:32 | Loss of consciousness, movement disorder, seizures, behavioral and psychological symptoms | None | 5 | 1 | 1 | 0 | Steroids, IVIg, Cyclophosphamide | Methylprednisolone (8 mg/day) | None | None | Topamax (150 mg/day), Sodium valproate (600 mg/day) | Topamax(50 mg/day) | Topamax(50 mg/day) | None | None | None |
| Patient_2 | F | 24 | 16 | 1:32 | Loss of consciousness, movement disorder, seizures, behavioral and psychological symptoms | None | 5 | 2 | 1 | 0 | Steroids, IVIg, Cyclophosphamide | Methylprednisolone (4 mg/day) | None | None | Sodium valproate (500 mg/day) | None | None | None | None | None |
| Patient_3 | F | 25 | 12 | 1:32 | Loss of consciousness, movement disorder, seizures, behavioral and psychological symptoms | Teratoma | 5 | 2 | 1 | 0 | Steroids, IVIg, Rituximab, Cyclophosphamide, Surgical removal of teratoma | Methylprednisolone (8 mg/day) | Methylprednisolone (4 mg/day) | None | Levetiracetam (500 mg/day) | None | None | None | None | None |
| Patient_4 | M | 28 | 16 | 1:32 | Loss of consciousness, movement disorder, seizures, behavioral and psychological symptoms | None | 5 | 2 | 1 | 0 | Steroids, IVIg, Cyclophosphamide | Methylprednisolone (8 mg/day) | None | None | Oxcarbazepine (600 mg/day), Topamax (50 mg/day) | None | None | None | None | None |
| Patient_5 | M | 31 | 12 | 1:32 | Loss of consciousness, movement disorder, seizures, behavioral and psychological symptoms | None | 5 | 1 | 1 | 0 | IVIg, Cyclophosphamide | None | None | None | None | None | None | None | None | None |
| HCs_1 | F | 24 | 12 | |||||||||||||||||
| HCs_2 | F | 26 | 16 | |||||||||||||||||
| HCs_3 | F | 24 | 16 | |||||||||||||||||
| HCs_4 | M | 26 | 16 | |||||||||||||||||
| HCs_5 | M | 32 | 12 | |||||||||||||||||
CSF, cerebrospinal fluid; mRS, modified Rankin Scores; AEDs, antiepileptic drugs; IVIg, intravenous human immunoglobulin.